Illumina (0J8Z) Share Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0J8Z Analyst Ratings

Moderate Buy

9 Buy

6 Hold

3 Sell

Based on 18 analysts giving stock ratings to

Illumina

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0J8Z Stock 12 Month Forecast

Average Price Target

$257.44

▲(14.35% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Illumina in the last 3 months. The average price target is $257.44 with a high forecast of $310.00 and a low forecast of $113.00. The average price target represents a 14.35% change from the last price of $225.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"99":"$99","152":"$152","205":"$205","258":"$258","311":"$311"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":310,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$310.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":257.44444444444446,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$257.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":113,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$113.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[99,152,205,258,311],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,266.07,269.4492307692308,272.8284615384615,276.2076923076923,279.5869230769231,282.9661538461538,286.3453846153846,289.7246153846154,293.1038461538462,296.4830769230769,299.8623076923077,303.2415384615385,306.6207692307692,{"y":310,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,266.07,265.40649572649573,264.7429914529915,264.07948717948716,263.4159829059829,262.75247863247864,262.0889743589744,261.42547008547007,260.7619658119658,260.09846153846155,259.4349572649573,258.771452991453,258.1079487179487,{"y":257.44444444444446,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,266.07,254.29538461538462,242.52076923076922,230.74615384615385,218.97153846153844,207.19692307692307,195.4223076923077,183.6476923076923,171.87307692307692,160.09846153846155,148.32384615384615,136.54923076923077,124.7746153846154,{"y":113,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":100.785,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.436,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":129.519,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":131.389,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":141.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.79,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.05,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.41,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":164.13,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.19,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.66,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":208.56,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":266.07,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$310.00

Average Price Target$257.44

Lowest Price Target$113.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kyle Mikson CFA

Canaccord Genuity

$300

Hold

33.25%

Upside

Reiterated

10/30/26

Canaccord Genuity Remains a Hold on Illumina (ILMN)

David Westenberg

Piper Sandler

$305

Buy

35.47%

Upside

Reiterated

10/30/26

Piper Sandler Keeps Their Buy Rating on Illumina (ILMN)

Luke Sergott

Barclays

$200

Sell

-11.17%

Downside

Reiterated

10/30/26

Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (NASDAQ: PHAT), Alnylam Pharma (NASDAQ: ALNY) and Illumina (NASDAQ: ILMN)

Casey Woodring

J.P. Morgan

$320→$300

Buy

33.25%

Upside

Reiterated

10/30/26

Analysts Are Bullish on These Healthcare Stocks: Illumina (ILMN), Alignment Healthcare (ALHC)

Daniel Arias

Stifel Nicolaus

$225→$300

Buy

33.25%

Upside

Reiterated

10/30/26

Illumina price target raised to $300 from $225 at StifelIllumina price target raised to $300 from $225 at Stifel

Vijay Kumar

Evercore ISI

$290→$275

Buy

22.15%

Upside

Reiterated

10/30/26

Illumina price target lowered to $275 from $290 at Evercore ISIIllumina price target lowered to $275 from $290 at Evercore ISI

Subbu Nambi

Guggenheim

$305

Buy

35.47%

Upside

Reiterated

10/29/26

Analysts Are Bullish on These Healthcare Stocks: Phathom Pharmaceuticals (PHAT), Genmab (GMAB)

Dan Leonard

RBC Capital

$310

Buy

37.69%

Upside

Reiterated

10/29/26

RBC Capital Sticks to Its Buy Rating for Illumina (ILMN)

Lu Li

Bank of America Securities

$168→$200

Sell

-11.17%

Downside

Reiterated

10/29/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Illumina (NASDAQ: ILMN)

Unknown Analyst

Robert W. Baird

Not Ranked

Robert W. Baird

$286

Hold

27.03%

Upside

Reiterated

10/27/26

Robert W. Baird Remains a Hold on Illumina (ILMN)

Mason Carrico

Stephens

$213→$275

Hold

22.15%

Upside

Downgraded

10/23/26

Illumina downgraded to Equal Weight from Overweight at StephensIllumina downgraded to Equal Weight from Overweight at Stephens

Eve Burstein

Bernstein

$215

Hold

-4.50%

Downside

Assigned

10/19/26

Analysts Offer Insights on Healthcare Companies: Illumina (NASDAQ: ILMN), United Therapeutics (NASDAQ: UTHR) and BeOne Medicines (NASDAQ: ONC)

Daniel Brennan

TD Cowen

$210→$270

Hold

19.93%

Upside

Reiterated

10/13/26

Illumina price target raised to $270 from $210 at TD CowenIllumina price target raised to $270 from $210 at TD Cowen

Puneet Souda

Leerink Partners

$220→$300

Buy

33.25%

Upside

Reiterated

09/29/26

Leerink Partners Sticks to Their Buy Rating for Illumina (ILMN)

Doug Schenkel

UBS

$135→$260

Buy

15.48%

Upside

Upgraded

09/09/26

Illumina assumed with a Buy at UBSIllumina assumed with a Buy at UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kyle Mikson CFA

Canaccord Genuity

$300

Hold

33.25%

Upside

Reiterated

10/30/26

Canaccord Genuity Remains a Hold on Illumina (ILMN)

David Westenberg

Piper Sandler

$305

Buy

35.47%

Upside

Reiterated

10/30/26

Piper Sandler Keeps Their Buy Rating on Illumina (ILMN)

Luke Sergott

Barclays

$200

Sell

-11.17%

Downside

Reiterated

10/30/26

Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (NASDAQ: PHAT), Alnylam Pharma (NASDAQ: ALNY) and Illumina (NASDAQ: ILMN)

Casey Woodring

J.P. Morgan

$320→$300

Buy

33.25%

Upside

Reiterated

10/30/26

Analysts Are Bullish on These Healthcare Stocks: Illumina (ILMN), Alignment Healthcare (ALHC)

Daniel Arias

Stifel Nicolaus

$225→$300

Buy

33.25%

Upside

Reiterated

10/30/26

Illumina price target raised to $300 from $225 at StifelIllumina price target raised to $300 from $225 at Stifel

Vijay Kumar

Evercore ISI

$290→$275

Buy

22.15%

Upside

Reiterated

10/30/26

Illumina price target lowered to $275 from $290 at Evercore ISIIllumina price target lowered to $275 from $290 at Evercore ISI

Subbu Nambi

Guggenheim

$305

Buy

35.47%

Upside

Reiterated

10/29/26

Analysts Are Bullish on These Healthcare Stocks: Phathom Pharmaceuticals (PHAT), Genmab (GMAB)

Dan Leonard

RBC Capital

$310

Buy

37.69%

Upside

Reiterated

10/29/26

RBC Capital Sticks to Its Buy Rating for Illumina (ILMN)

Lu Li

Bank of America Securities

$168→$200

Sell

-11.17%

Downside

Reiterated

10/29/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Illumina (NASDAQ: ILMN)

Unknown Analyst

Robert W. Baird

Not Ranked

Robert W. Baird

$286

Hold

27.03%

Upside

Reiterated

10/27/26

Robert W. Baird Remains a Hold on Illumina (ILMN)

Mason Carrico

Stephens

$213→$275

Hold

22.15%

Upside

Downgraded

10/23/26

Illumina downgraded to Equal Weight from Overweight at StephensIllumina downgraded to Equal Weight from Overweight at Stephens

Eve Burstein

Bernstein

$215

Hold

-4.50%

Downside

Assigned

10/19/26

Analysts Offer Insights on Healthcare Companies: Illumina (NASDAQ: ILMN), United Therapeutics (NASDAQ: UTHR) and BeOne Medicines (NASDAQ: ONC)

Daniel Brennan

TD Cowen

$210→$270

Hold

19.93%

Upside

Reiterated

10/13/26

Illumina price target raised to $270 from $210 at TD CowenIllumina price target raised to $270 from $210 at TD Cowen

Puneet Souda

Leerink Partners

$220→$300

Buy

33.25%

Upside

Reiterated

09/29/26

Leerink Partners Sticks to Their Buy Rating for Illumina (ILMN)

Doug Schenkel

UBS

$135→$260

Buy

15.48%

Upside

Upgraded

09/09/26

Illumina assumed with a Buy at UBSIllumina assumed with a Buy at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AORTArtivion

MDWDMediwound

IMUXImmunic

RZLTRezolute

DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Illumina

3 Months

Dan LeonardRBC Capital

Success Rate

10/17 ratings generated profit

Average Return

+5.18%

Copying Dan Leonard's trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +5.18% per trade.

1 Year

Doug SchenkelUBS

Success Rate

26/33 ratings generated profit

Average Return

+18.94%

Copying Doug Schenkel's trades and holding each position for 1 Year would result in 78.79% of your transactions generating a profit, with an average return of +18.94% per trade.

2 Years

Doug SchenkelUBS

Success Rate

24/33 ratings generated profit

Average Return

+51.70%

Copying Doug Schenkel's trades and holding each position for 2 Years would result in 72.73% of your transactions generating a profit, with an average return of +51.70% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0J8Z Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0J8Z has received 19 Buy Ratings, 11 Hold Ratings, and 7 Sell Ratings. 0J8Z average Analyst price target in the past 3 months is 257.44.

Each month's total comprises the sum of three months' worth of ratings.

0J8Z Financial Forecast

0J8Z Earnings Forecast

Next quarter’s earnings estimate for 0J8Z is $1.53 with a range of $1.51 to $1.56. The previous quarter’s EPS was $1.44. 0J8Z beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0J8Z has Performed in-line its overall industry.

0J8Z Sales Forecast

Next quarter’s sales forecast for 0J8Z is $1.23B with a range of $1.22B to $1.23B. The previous quarter’s sales results were $1.13B. 0J8Z beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0J8Z has Performed in-line its overall industry.

0J8Z Stock Forecast FAQ

What is GB:0J8Z’s average 12-month price target, according to analysts?

Based on analyst ratings, Illumina’s 12-month average price target is 257.44.

What is GB:0J8Z’s upside potential, based on the analysts’ average price target?

Illumina has 14.35% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Illumina a Buy, Sell or Hold?

Illumina has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 6 hold ratings and 3 sell ratings.

What is Illumina’s share price target?

The average share price target for Illumina is 257.44. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $310.00 ,and the lowest forecast is $113.00. The average share price target represents 14.35% Increase from the current price of $225.14.

What do analysts say about Illumina?

Illumina’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Illumina?

To buy shares of GB:0J8Z, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Illumina (0J8Z) Share Forecast & Price Target

0J8Z Analyst Ratings

0J8Z Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Illumina

0J8Z Analyst Recommendation Trends

0J8Z Financial Forecast

0J8Z Earnings Forecast

0J8Z Sales Forecast

0J8Z Stock Forecast FAQ

Detailed List of Analyst Forecasts